Methods and dosing regimens using ibudilast and a second agent for cancer therapy
Inventors
Matsuda, Kazuko • McDonald, Kerrie
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11446283-B2
Publication Date
2022-09-20
Expiration Date
Abstract
Methods and dosing regimens for treating glioblastoma or recurrent glioblastoma and its associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) or a pharmaceutically acceptable salt thereof and at least one or more other therapeutic agent.
Core Innovation
The invention provides a method of treating a patient diagnosed with glioblastoma or suffering from recurrent glioblastoma by administering ibudilast or a pharmaceutically acceptable salt thereof together with at least one or more other therapeutic agent. The at least one or more other therapeutic agent is selected from temozolomide (TMZ), carmustine, bevacizumab, procarbazine, hydroxyurea, irinotecan, lomustine, nimotuzumab, sirolimus, mipsagargin, cabozantinib, onartuzumab, patupilone (epothilone B), recombinant oncolytic poliovirus (PVS-RIPO), or any combination of one or more of the foregoing.
The method defines a dosing-cycle structure in which ibudilast and the at least one other therapeutic agent are administered during an optionally repeating dosing cycle lasting from about 20 to about 40 days. Within each dosing cycle, the at least one other therapeutic agent is administered during only the first about 3 to about 7 days of each dosing cycle, while ibudilast is administered throughout the dosing cycle.
The method further specifies that the patient expresses unmethylated MGMT and that ibudilast or a pharmaceutically acceptable salt thereof is administered orally. The document describes examples including ibudilast in combination with TMZ and discussion of dosing cycles and oral administration.
Claims Coverage
Independent claim clm-00001 provides five main inventive features.
Oral ibudilast with specified combination anti-cancer agents
Administering ibudilast or a pharmaceutically acceptable salt thereof with at least one or more other therapeutic agent selected from temozolomide (TMZ), carmustine, bevacizumab, procarbazine, hydroxyurea, irinotecan, lomustine, nimotuzumab, sirolimus, mipsagargin, cabozantinib, onartuzumab, patupilone (epothilone B), recombinant oncolytic poliovirus (PVS-RIPO), or any combination of one or more of the foregoing, wherein ibudilast or a pharmaceutically acceptable salt thereof is administered orally.
Optionally repeating 20 to 40 day dosing cycle
Administering ibudilast or a pharmaceutically acceptable salt thereof and the at least one or more other therapeutic agent during an optionally repeating dosing cycle lasting from about 20 to about 40 days.
Other therapeutic agent limited to first 3 to 7 days of each cycle
Administering the at least one or more other therapeutic agent during only the first about 3 to about 7 days of each dosing cycle.
Unmethylated MGMT patient selection
Treating the patient in which the patient expresses unmethylated MGMT.
Recurrent glioblastoma treatment context
Providing a method of treating a patient diagnosed with glioblastoma or suffering from recurrent glioblastoma.
The claim coverage is centered on a glioblastoma or recurrent glioblastoma treatment method using orally administered ibudilast in combination with a specified other therapeutic agent, delivered in optionally repeating dosing cycles of about 20 to about 40 days with the other therapeutic agent restricted to only the first about 3 to about 7 days, and limited to patients expressing unmethylated MGMT.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treating a patient diagnosed with glioblastoma or suffering from recurrent glioblastoma using ibudilast in combination with a specified other therapeutic agent.
Interested in licensing this patent?